4.3 Review

delta-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches

Journal

SKELETAL MUSCLE
Volume 1, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/2044-5040-1-13

Keywords

-

Categories

Funding

  1. Heart Research UK
  2. AFM
  3. Medical Research Council [G0601943] Funding Source: researchfish
  4. MRC [G0601943] Funding Source: UKRI

Ask authors/readers for more resources

Mutations in the delta-sarcoglycan gene cause limb-girdle muscular dystrophy 2F (LGMD2F), an autosomal recessive disease that causes progressive weakness and wasting of the proximal limb muscles and often has cardiac involvement. Here we review the clinical implications of LGMD2F and discuss the current understanding of the putative mechanisms underlying its pathogenesis. Preclinical research has benefited enormously from various animal models of delta-sarcoglycan deficiency, which have helped researchers to explore therapeutic approaches for both muscular dystrophy and cardiomyopathy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available